PERSPECTIVE

THROUGH AND BEYOND COVID-19 PANDEMIC: A NEW SCENARIO FOR CARDIONCOLOGY

L. Tarantini 1, A. Camerini 2, M. L. Canale 3, I. Bisceglia 4, D. Gabrielli 5, F. Colivicchi 6, M. M. Gulizia 7,8, A. Navazio 1

1 Department of Cardiology, Presidio Ospedaliero - Santa Maria Nuova, AUSL RE IRCCS, Reggio Emilia, Italy
2 Medical Oncology, Azienda USL Toscana Nord-Ovest, Versilia Hospital, Lido di Camaiore, Lucca, Italy
3 Division of Cardiology, Azienda USL Toscana Nord-Ovest, Versilia Hospital, Lido di Camaiore, Lucca, Italy
4 Department of Cardio-Thoracic-Vascular, Integrated Cardiology Services, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
5 Department of Cardio-Thoracic-Vascular, Cardiology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
6 Department of Clinical and Rehabilitation Cardiology, Presidio Ospedaliero San Filippo Neri, ASL Roma 1, Rome, Italy
7 Department of Cardiology, Azienda di Rilievo Nazionale e Alta Specializzazione Garibaldi, Catania, Italy
8 Fondazione per il Tuo cuore - Heart Care Foundation, Florence, Italy

CORRESPONDING AUTHOR:
Luigi Tarantini
Department of Cardiology
Presidio Ospedaliero - Santa Maria Nuova, AUSL RE IRCCS
viale Risorgimento 80
42123 Reggio Emilia, Italy
E-mail: luigi.tarantini@gmail.com; luigi.tarantini@ausl.re.it
ORCID: 0000-0003-2580-0963

Doi: 10.48286/aro.2021.27

History
Received: Sept 16, 2021
Accepted: Nov 11, 2021
Published: Dec 1, 2021

ABSTRACT

Covid-19 pandemic has completely overthrown health system organization but at the same time it has provided the proof that the patterns of care could rapidly adapt to new circumstances. Social distancing and limited access to hospitals have proven to be a valid tool to reduce Sars-Cov2 infection but they could be useful to control many other infective diseases, especially for frail patients as people with cancer are. In a model of chronic care for long-term cancer patients and/or within a survivorship program for cured patients, Cardioncology should built upon the experience of Covid pandemic and set new management strategies to provide top level care for a wide and increasing patient population. Telemedicine, patients and caregivers empowerment together with dedicated resources are mandatory to set a real change in cardiac care for cancer patients through and beyond pandemic.
INTRODUCTION

After more than one year since the outbreak of Covid-19 crisis the pandemic is still in full swing. The appearance of aggressive viral variants and the difficulties in achieving vaccination coverage in general population do not allow us to define with certainty when we will be able to overcome the Covid-19 epidemic. What we certainly know is that social distancing and controlled/limited access to places at greatest risk of infection, such as hospitals, represent even now the most effective measures in containing Sars-Cov2 infection. Furthermore, the management of the Covid-19 disease caused a significant stress to health systems organization as entire hospitals or hospital wards have been shifted towards the exclusive treatment of the disease so limiting the available resources dedicated to the management of other diseases. Consequently covid-19 pandemic had significant impact on the management of illness not directly connected with Sars-Cov2 infection. Even in March 2021, for example, in Piedmont an important region in Northern Italy, all elective hospital admissions not directly connected with covid-19 have been suspended again for the spread of the third epidemic wave (1). During the first phase of the Covid-19 pandemic, we have witnessed an increased incidence of patients with complicated or “delayed” acute myocardial infarction presentation (2) and the same occurred for heart failure (3). In clinical oncology practice the Covid-19 pandemic had significant negative effects reducing screening activities and oncological surveillance programs (4-7) with a possible increase of cancer mortality (7, 8). For such reasons, uncertainty in predicting when we will overcome the Covid-19 crisis imposes substantial reflection also in Cardioncology practice to prevent and effectively treat cardiotoxicity. Indeed, patients with active cancer or those treated with cardiotoxic therapies may have heart damages exacerbated by SARS-CoV-2 infection than non-cancer patients. SARS-CoV-2 infection leads to secondary hemophagocytic lymph histiocytosis (sHLH), which is a multiorgan hyperinflammatory condition based on the hyperactivation of cytotoxic T lymphocytes, macrophages, and natural killer cells, leading to multiorgan failure (including myocarditis, venous thromboembolism, and acute respiratory distress syndrome) and consequently to death (9). However, the Covid-19 “crisis” can represent an opportunity to create new management strategies that can help overcome some problems that in the past prevented the full development and spread of Cardioncology programs.

KEY WORDS
Cardioncology; Covid-19; cancer survivors; telemedicine.

IMPACT STATEMENT

The crisis caused by Covid-19 requires the remodeling of cardioncology in order to avoid the Sars-COV-2 infection. Telemedicine and the re-engineering of management algorithms can represent a valid tool for the prevention and treatment of cardiotoxicity.

CARDIONCOLOGY: THE NEW MAGMATIC AND MOVING SPECIALIZATION OF CARDIOLOGY

Patients with cancer often have coexisting cardiovascular (CV) risk factors that must be appropriately managed and followed even in the medium to long-term considering the success of current oncological therapies (10, 11). The new therapies introduced for the treatment of cancer in recent years, indeed, if on the one hand has revolutionized and improved the prognosis of many neoplasms, on the other hand can cause a wide spectrum of short- and long-term cardiotoxic effects beyond heart failure. A practical example is represented by the need to check the ECG, blood pressure, lipid, glycemic homeostasis in patients on treatment with drugs able to lengthen the QT or for those which interfere with vascular/metabolic homeostasis (12) to prevent arrhythmias or cardiac ischemic complications. For a successful management program, a fundamental point in the evolving field of Cardioncology is the collaboration and sharing of multi-specialist skills during all phases of the cancer therapeutic program (figure 1) (13, 39).
improvement in patient survival resulted in the birth of a new and growing category of “long-living” cancer patients with the need for multidisciplinary periodic checks to avoid late cardiac complications due to progressive myocardial dysfunction or accelerated atherosclerosis. This is also (and especially) true for patients with metastatic cancer in ongoing therapy. Currently, the management of oncological disease in networked hospitals can pose logistical problems related to patient transfers and the relocation of specialist structures to different hospitals. Nowadays the daily calendar of cancer patients in active treatment is full of commitments and hospital contacts between blood samples, imaging tests, radiotherapy session, cyclic therapy infusions and set “timely” scheduled controls of different specialties, as cardiological evaluation and relative diagnostic tests, could represent a problem overall for patients who live far from reference centers or for those who present a condition of disability and non-self-sufficiency. These logistical (and organizational) aspects, a real problem to implement cardioncology programs in some centers in pre covid-19 time, became even more important and generalized in the period of the Covid-19 pandemic due to the limitation or deletion of scheduled hospital visits to limit the exposure of patients and health-care professionals. Furthermore, social distancing and limitation to access had a negative influence also for rehabilitation programs and therefore prevented the development or continuation of prevention and rehabilitation programs, one of the most promising sections of cardioncology overall in the field of long-living cancer patients (14, 15).

The central question that the covid-19 crisis forces us to ask ourselves is therefore: how can we create an effective and efficient management program in Cardioncology while maintaining social distancing, limiting access to the hospital and possibly not increase the financial costs of management?

---

**TELEMEDICINE: FROM SOLUTION DURING PANDEMIC TO VALID OPPORTUNITY FOR THE DEVELOPMENT OF CARDIONCOLOGY BEYOND COVID-19**

Covid-19 outbreak “scenario” gave impetus to development and diffusion of telemedicine (16, 17), a practice that allows to maintain contact with the patient and at the same time respect the distance, thus reducing the risk of infection. The progression

---

**Figure 1.** Cardio-oncology: rationale and pathways for cancer patients. Modified by Lancellotti (13).

C.T.: Cancer Treatments; CVD: Cardiovascular disease; CV: cardiovascular; ECG: electrocardiogram; *: Anthracyclines, anti-HER2 therapies, VEGF or BCR-ABL targeted TKIs, proteosomal inhibitors, and thoracic radiotherapy. TKI: tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
towards electronic health records has facilitated the sharing of information between different categories of specialists involved in patient care and in different settings (hospital and outpatients) hence improving continuity of care. Virtual platforms have proved useful instruments for multidisciplinary discussion and video consultation with staff involved in patient care, with the patient himself or caregiver in family environment. The spread of telemonitoring employing mobile phones allows us remote control of useful parameters such as oxygen saturation, blood pressure, ECG, glycemic values in diabetics. Since the beginning of the COVID-19 pandemic, several initiatives have been launched on the use of telemedicine to check and control atrial fibrillation (18), diabetes (19), hypertension (20), and heart failure (21-23), clinical conditions common also in the cardioncology practice. Preliminary clinical experience suggests the technological improvement may support also the synchronous telehabilitation programs (24). Finally, social media represent one potential opportunity to disseminate information about cardio-oncology promoting educational/advocacy campaign to a large audience (25). Another remark makes telemedicine appealing, COVID-19 “crisis” has also severely affected the global economy. Significant reductions in income, a rise in unemployment, and disruptions in the transportation, service, and manufacturing industries are among the consequences of the Covid-19 pandemics the effects of which will be increasingly relevant as the epidemic continues and likely will have repercussions for a long time after we emerge from the current situation of uncontrolled covid-19 outbreak. The economic consequences will be amplified by heterogeneous income distribution across the country causing a potential inequality in care and consequently a loss of effectiveness and efficiency of health systems including universalistic ones (26). Social and economic factors are emerging as relevant factors conditioning the prognosis of cancer (27, 28) and heart disease (29, 30), real-world evidence underscores the importance of not neglecting these factors also in cardioncology (31, 32). A “syndemic” approach tacking in consideration the intimate intersection between clinical, economic, and social factors could help to face “complex” situation as often happens to meet in the practice of cardioncology. By preserving interpersonal connectivity and therefore reducing distances, telemedicine can mitigate social/geographic isolation, improve the circulation of information, and most probably reduce the costs deriving from saving time and money for transport. The routine video consultation aimed at not losing contact with the patient can also be performed by dedicated nursing staff who, in addition to having a positive effect on compliance and adherence to clinical recommendations and prevention programs, can operate as a “navigator” to select patients who need traditional “face-to-face” clinical visits. In order to improve patients’ compliance to both virtual and in-person activities, a personalized empowerment program should be proposed. Caregivers (mainly within the family unit) play a pivotal role in such process and should consequently be part of this program (33).

IN SEARCH OF THE “HOLY GRAIL”: DEVELOP AND IMPLEMENTING CARDIONCOLOGY AFTER THE COVID-19 CRISIS

The main purpose of Cardioncology is to assists in the overall care of cancer patients, with and without cardiovascular disease, in an interdisciplinary way sharing responsibilities and experiences among health-care team members to reduce cancer therapeutics-related cardiovascular complications and improve clinical outcomes. This collaborative model results in completion of cancer therapy in most patients (34-37) nevertheless we are still far from having established reference standards on the structural level (38, 39) and scientific level (9, 41-43). However, it is worth remembering there are currently no established benchmarks to guide clinicians regarding timely access and assessment of patients. Cardioncology is not bound by a traditional and inflexible patient-care relationship. Patients receiving active cancer treatment generally require a faster access for basal evaluation with periodic hospital-based surveillance check-up during the completion of therapeutic program. Important variables which influence the frequency of checks are the potential cardiotoxicity of agents, the clinical status of patients including cardiac history and presence/absence of comorbidity. Over the years, combined with this “traditional” activity, the progressive increase in long-lived cancer patients has led to the creation of some outpatient clinics dedicated to the surveillance of late cardiot-
The Covid-19 outbreak heavily conditioned the cardioncology routine care in relation to the concern about Sars-COV2 infection, the measure for quarantine isolation and the inevitable reallocation of medical resources. Specific scenarios and algorithms for cardioncology have been suggested to manage patient during the outbreak of covid-19 (44-47) aimed to secure a separate and protected access to oncology, hematology and cardio-oncology departments and clinics without compromise the cardioncology consultation. These proposals have in common some key points as the accurate risk identification at basal evaluation of patients, a more intensive use of telehealth, a more stringent use of traditional hospital-based imaging assessments to be integrated with alternative methods such as biomarkers, easier to perform during periodic follow-up blood tests or drug infusion sessions. Preliminary experiences indicate that the remodeling of cardioncology activity through the integration of traditional “in-person” and “virtual” telemedicine care is achievable (47). Although we do not have the comparison results with respect to the traditional management method, it is reasonable to assume that in the future we will have to reformulate our way of working (table I) and that this is a way to be pursued for at least three reasons:

1. the lesson we have learned from Covid-19 is that our globalized society, interconnected and with a growing economic/social gap causes different responses from different healthcare systems, favoring the spread of infectious diseases such as those caused by highly infectious Sars-Cov2 virus capable of mutate rapidly. The “wave” course of Covid-19 requires the creation of flexible management models capable to rapidly respond to and contain the outbreak through isolation and social distancing without losing contact with patients and compromising the effectiveness of cancer treatments.

2. The Covid-19 outbreak has caused the cancellation of many scheduled visits with most of them should be reprogrammed. Wave trend of the COVID-19 epidemic with periodic remissions and resurgence impose the maintenance of safety protocols such as the separation of Covid hospitals from the Covid-19 “free” ones, or the extension of the time of medical and sanitary services to maintain social distancing and to allow the sanitation of environments and equipment. It will be exceedingly difficult reabsorb in a reasonable time the missed controls and, at the same time, guarantee an appropriate and “timely” management of new cases.

3. In the last few years there has been a real revolution in the field of oncological treatments, new drugs have been launched and innovative therapies have been developed such as immunotherapy with immune-check point inhibitors and Car-T. Cardiological surveillance is often required in many of these cases, thus expanding the horizon and the volume of activity of cardioncology clinics. There is, therefore, a need to reshape the surveillance and care pathways to avoid the repetition of unnecessary visits and examinations without denying specialist cardiological support and losing contact with the patient. Such consideration is not trivial considering the increase of patients who respond favorably to cancer treatments and at risk of cardiotoxicity in a large group of individuals such as the elderly or frail patients.

However, the path is not easy, there are many challenges to be faced and problems to be solved. A first necessary consideration is related to telemedicine, which still requires an enhancement in its diffusion, in the definition and homologation in the standards, the clarification of the legal terms and finally the reimbursement and professional recognition. There are other aspects to consider regarding telemedicine. The cost of the equipment and the ability to use new technologies can be a problem for the application of this method in some groups of patients, a second, and no less important consideration is that it must be an integrative method and not a substitute for traditional approach. The crisis caused by Covid-19 has also had a significant impact on mental health and psychological balance (48), a relevant issue in patients with cancer. The remote contact with the use of telemedicine is useful for maintaining distance but is less effective for the emotional effects of isolation which in some cases can also be amplified if used as an alternative and not integrative method of the traditional “face to face” approach. A judicious and flexible use is therefore advisable, in order to avoid a sense of abandonment and detachment for patients. Another relevant issue concerns the use of biomarkers. Troponin or NT-proBNP (N-terminal pro-B-type natriuretic peptide), may be able to allow spacing out of the serial echocardiograms, which are standard cardio-oncology practice. Biomarkers
are relatively lower cost, lower risk, less invasive, and less COVID-19 exposure approach compared with imaging. Nevertheless, currently we do not have “solid” evidence available from cardiotoxicity surveillance. Moving to a primarily biomarker-based monitoring could compromise sensitivity and specificity of cardiotoxicity detection. Further research is needed on biomarkers to detect cardiotoxicity. This strategy can be considered on an individual basis, balancing risk of COVID-19 exposure and the patient's cardiotoxicity risk. Integration methods between biomarkers and imaging tests can be implemented such as performing “fast” echocardiogram focused on the ejection fraction by organizing the examination in appropriate spaces during access for oncological therapy sessions, or where feasible in sessions home assistance.

In conclusion, the Covid-19 pandemic, with more than 225 million cases and over 4.5 million deaths worldwide today (49), has upset our way of living and working and its effects will also extend for a long time once the pandemic has passed. It is difficult to hypothesize a return, at least in the short term, to the old organizational and clinical practice models (50) and cardioncology will be one of the subspecialty branches of cardiology that will be primarily involved. Despite the initial crisis we are learning to react, and the era of COVID-19 is teaching us new paradigms of medicine that will change the face of medical practice. Now has come the time to apply what we have learned in past in cardio-cancer in a more effective, easy, flexible, and far-reaching way.

**ETHICS**

**Funding**

There were no institutional or private fundings for this article.
Conflict of interests
The authors have declared no conflict of interests.

Authors’ contribution
All the authors contributed equally to conception, data collection, analysis and writing of this paper.

REFERENCES


